The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison

Maria-Victoria Mateos,Jesús F. San Miguel,Hartmut Goldschmidt,Pieter Sonneveld,Meletios A. Dimopoulos,Bart Heeg,M. Hashim,William Deraedt,Peter Hu,Annette Lam,Jianming He

The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison

2019

Maria-Victoria Mateos
Jesús F. San Miguel
Hartmut Goldschmidt
Pieter Sonneveld
Meletios A. Dimopoulos
Bart Heeg
M. Hashim
William Deraedt
Peter Hu
Annette Lam
Jianming He

AbstractFor patients with newly diagnosed multiple myeloma (NDMM) who are transplant ineligible, bortezomib-melphalan-prednisone (VMP) demonstrated superior efficacy based on the VISTA trial. In su...

Keywords:

Prednisone
Bortezomib
Medicine
Multiple myeloma
Melphalan
Diabetes mellitus
Oncology
Internal medicine
Immunology
transplant ineligible
indirect comparison
newly diagnosed

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations